share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Apr 10 17:28
Summary by Moomoo AI
Cybin Inc., a clinical-stage biopharmaceutical company, has announced that its CEO, Doug Drysdale, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024. The conference will be held in Toronto, Ontario, and Drysdale's presentation is scheduled to be webcast live at 1:30 p.m. ET. Cybin, known for developing innovative psychedelic treatment options for mental health conditions, is currently working on CYB003, a treatment for major depressive disorder, and CYB004 for generalized anxiety disorder. The company, which was founded in 2019, operates in multiple countries and continues to focus on advancing its proprietary drug discovery platforms and treatment regimens.
Cybin Inc., a clinical-stage biopharmaceutical company, has announced that its CEO, Doug Drysdale, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024. The conference will be held in Toronto, Ontario, and Drysdale's presentation is scheduled to be webcast live at 1:30 p.m. ET. Cybin, known for developing innovative psychedelic treatment options for mental health conditions, is currently working on CYB003, a treatment for major depressive disorder, and CYB004 for generalized anxiety disorder. The company, which was founded in 2019, operates in multiple countries and continues to focus on advancing its proprietary drug discovery platforms and treatment regimens.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more